NCI-2022-09157

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO) Her2 Radiation Optimization (HERO)

This is a Phase III randomized research study that is comparing radiotherapy optimization for low-risk HER2-positive breast cancer. It is investigating whether radiotherapy can be omitted for certain patients with low-risk HER2-positive breast cancer who are also receiving HER2-targeted therapy. The goal of the trial is to see if omitting radiation therapy is safe and effective for patients that could potentially reduce treatment burden and side effects for some patients.

HER-2 Positive: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

Radiotherapy: Radiotherapy to the whole breast/chest area and the surrounding lymph glands is called regional radiotherapy.

Phase III: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05705401

NCI-2022-09157

Clinical Trial Site: Einstein/Columbia

To see all available clinical trials click here.